SHANGHAI, Jan. 14, 2024 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical-stage innovative biopharmaceutical company, announced recently that the company has completed a Phase Ib study, 'An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period'. .

上海，2024年1月14日/PRNewswire/--Hope Medicine Inc.（“HopeMed”）是一家临床阶段创新性生物制药公司，最近宣布该公司已完成一项Ib期研究，“一项开放标签研究，旨在评估24周治疗期HMI-115治疗雄激素性脱发的男性和女性的安全性，耐受性和疗效”。。

This study is led by Professor Rodney Sinclair and included 12 male and 4 female patients in Australia with androgenic alopecia (AGA). HMI-115 demonstrated positive efficacy results. It is also safe and well-tolerated. Specifically, in the 12 male patients at the end of the trial, the mean non-vellus target area hair count (TAHC) increased by 14 hairs/cm2, compared to that of the baseline.

这项研究由罗德尼·辛克莱教授领导，包括澳大利亚12名男性和4名女性雄激素性脱发（AGA）患者。HMI-115显示出积极的疗效结果。它也安全且耐受性良好。具体而言，在试验结束时的12名男性患者中，与基线相比，平均非绒毛靶区毛发计数（TAHC）增加了14根毛发/cm2。

This increase is statistically significant indicating an apparent confidence of treatment effect..

这种增加具有统计学意义，表明治疗效果明显可信。。

'The positive outcome of this trial is very encouraging,' said Professor Rui-Ping Xiao, founder of Hope Medicine, 'this study is the first ever to show that prolactin receptor blockade can promote hair growth in patients with androgenic alopecia and may provide a novel therapeutic approach.'

“这项试验的积极结果非常令人鼓舞，”霍普医学创始人肖瑞平教授说，“这项研究首次证明催乳素受体阻断剂可以促进雄激素性脱发患者的头发生长，并可能提供一种新的治疗方法。”

'Encouraged by the success of this proof-of-concept trial,' said Nathan Chen, CEO, 'Hope Medicine has commenced recruitment for a Phase II study of AGA in China with 180 patients. We aim to achieve full PoC by the end of 2024.'

首席执行官内森·陈（NathanChen）说，受到这项概念验证试验成功的鼓舞，希望医学（Hope Medicine）已开始在中国招募180名患者进行AGA的II期研究。我们的目标是到2024年底实现全面PoC。”

About Androgenic Alopecia

关于雄激素性脱发

Androgenetic Alopecia is the most common type of hair loss and affects up to 70% of men and 40% of women. While male and female pattern hair loss is commonly believed to be due to a combination of genetics and the male hormone dihydrotestosterone, the detailed mechanism remains unclear. Our data points to a role of prolactin/prolactin-receptors signaling in the disorder. .

雄激素性脱发是最常见的脱发类型，影响多达70%的男性和40%的女性。虽然人们普遍认为男性和女性脱发是遗传因素和男性激素二氢睾酮共同作用的结果，但具体机制尚不清楚。我们的数据表明催乳素/催乳素受体信号在疾病中的作用。。

About Hope Medicine

关于希望医学

Hope Medicine Inc. is a science-driven clinical-stage biopharmaceutical company with research laboratories and offices in Beijing, Shanghai, and Nanjing, China. HopeMed is established on the in-depth expertise in translational medicine and decades of research of Professor Rui-Ping Xiao's laboratory at the College of Future Technology of Peking University.

Hope Medicine Inc.是一家科学驱动的临床阶段生物制药公司，在中国北京、上海和南京设有研究实验室和办事处。HopeMed建立在转化医学的深入专业知识和北京大学未来技术学院肖瑞平教授实验室数十年的研究基础上。

Based on excellent scientific research and to improve the quality of life, HopeMed is committed to the research, development, and commercialization of first-in-class medicines for common and major diseases that threaten human health. The company finalized a Round B financing in May 2021 following a worldwide exclusive license agreement with Bayer AG on the development and commercialization of HMI-115.

基于卓越的科学研究和提高生活质量，HopeMed致力于研究，开发和商业化一流的药物，用于威胁人类健康的常见和重大疾病。在与拜耳公司就HMI-115的开发和商业化达成全球独家许可协议后，该公司于2021年5月完成了B轮融资。

Besides HMI-115, HopeMed also established a diversified pipeline with internal R&D based on Professor Xiao's breakthrough research at the Institute of Molecular Medicine (IMM) at Peking University via a joint research lab. As a result, HopeMed brought in MG53 from Peking University, which is a protein with a new target.

除了HMI-115之外，HopeMed还通过联合研究实验室，在肖教授在北京大学分子医学研究所（IMM）的突破性研究基础上，建立了一条多元化的内部研发管道。因此，HopeMed从北京大学引进了MG53，这是一种具有新靶标的蛋白质。

Preclinical studies have shown that this protein has a promising therapeutic effect on indications such as acute myocardial infarction..

临床前研究表明，这种蛋白质对急性心肌梗死等适应症具有良好的治疗效果。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements that are primarily based on the current outlook, expectations, estimates, and projections of the company's management team. When using 'anticipate,' 'believe,' 'may,' 'design,' 'effect,' 'assess,' 'expect,' 'predict,' 'target,' 'aim,' 'purpose' and any other similar words and expressions, in references to the company, the intention of the statement is forward-looking.

本新闻稿包含前瞻性声明，主要基于公司管理团队的当前前景、期望、估计和预测。在提及公司时，使用“预期”、“相信”、“可能”、“设计”、“效果”、“评估”、“预期”、“预测”、“目标”、“目标”、“目的”和任何其他类似的词语和表达时，声明的意图是前瞻性的。

Forward-looking statements are subject to risks and uncertainties, many of which are difficult to predict and often beyond the company's control, which could cause actual results to differ from the forward-looking statements. The company undertakes no public announcement obligation to update or revise any forward-looking statement..

前瞻性陈述具有风险和不确定性，其中许多风险和不确定性很难预测，并且往往超出公司的控制范围，这可能导致实际结果与前瞻性陈述不同。公司不承担更新或修订任何前瞻性声明的公告义务。。

CONTACT: Amber Chen, pr@hopemedinc.com

联系人：陈，pr@hopemedinc.com

SOURCE Hope Medicine Inc.

SOURCE Hope Medicine公司。